Olaratumab Brand Name– LARTRUVO
What is Olaratumab
Olaratumab is a human monoclonal antibody that binds platelet-derived growth factor receptor-alpha (PDGFR-alpha).
It is indicated in combination with doxorubicin for the treatment of soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery.
The median progression-free survival and overall survival times were significantly improved in patients with locally advanced or metastatic soft-tissue sarcoma who received olaratumab plus doxorubicin compared with doxorubicin alone in a multicenter, randomized, phase II trial (n = 133).
Olaratumab was approved by the FDA in 2016.
Indications
- soft-tissue sarcoma
For the treatment of soft-tissue sarcoma
NOTE: Olaratumab has been designated as an orphan drug for the treatment of soft-tissue sarcoma.
for the treatment of soft-tissue sarcoma not amenable to curative treatment with radiotherapy or surgery, in combination with doxorubicin
Side Effects
- abdominal pain
- abdominal pain
- alopecia
- anaphylactic shock
- anorexia
- anorexia
- anxiety
- arthralgia
- arthralgia
- asthenia
- asthenia
- back pain
- back pain
- bone pain
- bone pain
- bronchospasm
- cardiac arrest
- chills
- chills
- diarrhea
- diarrhea
- elevated hepatic enzymes
- fatigue
- fatigue
- fever
- fever
- flank pain
- flank pain
- flushing
- flushing
- headache
- hyperglycemia
- hyperglycemia
- hypokalemia
- hypokalemia
- hypomagnesemia
- hypophosphatemia
- hypophosphatemia
- hypotension
- hypotension
- infusion-related reactions
- infusion-related reactions
- lymphopenia
- lymphopenia
- muscle cramps
- muscle cramps
- musculoskeletal pain
- musculoskeletal pain
- myalgia
- myalgia
- nausea
- nausea
- neutropenia
- neutropenia
- oral ulceration
- oral ulceration
- peripheral neuropathy
- prolonged bleeding time
- prolonged bleeding time
- thrombocytopenia
- thrombocytopenia
- vomiting
- xerophthalmia
Monitoring Parameters
- CBC with differential
Contraindications
- breast-feeding
- contraception requirements
- infection
- infertility
- infusion-related reactions
- neutropenia
- pregnancy
- reproductive risk
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
Palifermin: (Moderate) Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents.
Penicillamine: (Major) Do not use penicillamine with antineoplastic agents due to the increased risk of developing severe hematologic and renal toxicity.
Tuberculin Purified Protein Derivative, PPD: (Moderate) Immunosuppressives may decrease the immunological response to tuberculin purified protein derivative, PPD. This suppressed reactivity can persist for up to 6 weeks after treatment discontinuation. Consider deferring the skin test until completion of the immunosuppressive therapy.
